Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global anticoagulants market was valued at US$ 30.15 billion in 2020 and is expected to register a revenue CAGR of 7.3% to reach US$ 65.44 billion by 2031.

Anticoagulants Market Fundamentals

Anticoagulants, commonly known as blood thinners, are drugs that help prevent the formation of a blood clot. They also keep existing blood clots from getting larger. A blood clot is a seal created by the blood to stop bleeding from wounds. While they are useful in stopping bleeding, they can block blood vessels and prevent blood from flowing to organs, such as the brain, heart, or lungs, if they form in the wrong place. Anticoagulants are prescribed to individuals at a high risk of forming clots to reduce the possibilities of developing serious conditions, such as strokes and heart attacks.

[8989]

Anticoagulants Market Dynamics

The global anticoagulants market is driven by rising geriatric population, rising prevalence of deep vein thrombosis (DVT), atrial fibrillation (AF), and stroke, and growing demand for anticoagulant therapy. Furthermore, growing adoption of novel oral anticoagulants (NOACs) is also likely to contribute to revenue growth of the market.

However, the high cost of NOACs and stringent regulations pertaining to drug approvals are likely to restrain the market revenue growth to a certain extent.

The COVID-19 pandemic has also resulted in a significant spike in the uptake of anticoagulants. This also intensified the pace of research to develop novel anticoagulant agents to the market. Several clinical trials have been underway to assess many pipeline drugs with potential treatment for COVID-19 patients. Therefore, the COVID-19 pandemic has had significant direct and indirect implications on the revenue growth of this market.

Anticoagulants Market Ecosystem

The global anticoagulants market is analyzed based on four parameters: drug class, application, and region.

Anticoagulants Market by Drug Class

[4567]

Based on the drug class, market is segmented into novel oral anticoagulants (NOACs), vitamin K antagonist, heparin and low molecular weight heparin (LMWP), and others (calcium complexing agents).

The novel oral anticoagulants (NOACs) segment dominated the market with the largest revenue share in 2020. This can be attributed to advantages of NOACs over other drug classes, such as their high efficacy in preventing stroke in AF, convenience of use, minor drug and food interactions, rapid onset and offset of action, and short half-life. NOACs are a new anticoagulant drug class also characterized by shorter half-like and used in prevention and treatment of myocardial infraction, pulmonary embolism, atrial fibrillation, and deep vein thrombosis.

Anticoagulants Market by Application

Based on the application, the anticoagulants market is segmented into deep vein thrombosis (DVT), pulmonary embolism, myocardial infarction (MI), atrial fibrillation (AF), and others (cerebrovascular disease, defibrinated syndrome, and hemodialysis).

The atrial fibrillation (AF) segment dominated the market with the largest revenue share in 2020. This can be ascribed to high incidence rate of AF and rising usage of anticoagulants in AF to reduce the risk of stroke.

Anticoagulants Market by Region

Based on the region, the global anticoagulants market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).

North America dominated the anticoagulants market with the largest revenue share in 2020, followed by Asia Pacific. The large revenue share of North America in the global market can be attributed to its developed healthcare infrastructure, rising prevalence of myocardial infarction (MI) and atrial fibrillation (AF), increasing demand for anticoagulation therapy, presence of prominent players, and growing R&D activities in the region.

Anticoagulants Market Competitive Landscape

The prominent players operating in the anticoagulants market are: -

• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd
• Siemens Healthcare GmbH
• Bayer AG
• Daiichi Sankyo Company, Limited
• Pfizer Limited.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim
• Amphastar Pharmaceuticals, Inc.
• Leo Pharma Inc.

Anticoagulants Market Strategic Developments

• In December 2020, Natco Pharma announced the launch of its novel oral anti-coagulant Rivaroxaban molecule under the brand RPIGAT in India
• In June 2020, Lonza announced a partnership agreement with Anthos Therapeutics, a biotech company created by Blackstone Life Sciences and Novartis, for the development and manufacturing of abelacimab, a novel factor XI and XIa antibody, which could address a range of thrombotic disorders

Frequently Asked Questions About This Report